HomeJobsSensodyne-Maker Haleon To Shut UK Manufacturing Site, With More Than 400 Jobs...

Sensodyne-Maker Haleon To Shut UK Manufacturing Site, With More Than 400 Jobs Hit | ESM Magazine


Related stories

83 FREE Business Events To Attend In June 2024 – Startups.co.uk

Every entrepreneur knows how lonely starting a business...

This UK-based budget airline is one of the world’s top five

Whether it’s a narrow seats, no leg room, or...

‘Extraordinary’ 4,000-year-old Egyptian skull may show attempts to treat cancer

An ‘extraordinary’ 4,000-year-old Egyptian skull shows signs of attempts...

Your star sign’s tarot horoscope for the month of June 2024

It’s a Gemini-heavy month, with the sign’s season now...

Consumer healthcare company Haleon is planning to shut down its manufacturing site in Britain by 2026, which will impact 435 jobs, a spokesperson told Reuters.

‘Following a strategic review of our global manufacturing capabilities, we have determined that our Maidenhead site is no longer a viable option for the manufacture of our products,’ the spokesperson said.

The Maidenhead site, located in Berkshire, England produces some of the FTSE 100 group’s most popular oral health brands such as Sensodyne toothpaste and Parodontax mouthwash.

The making of toothpastes will be transferred to Haleon’s hub in Slovakia, while mouthwash production will be moved to a third party contract manufacturer, details of which have yet to be announced.

Cost-Cutting Programme

Haleon has been focused on cutting its huge debt pile by selling brands such as Lamisil and Chapstick and keeping a lid on costs, after being spun-off from drugmaker GSK in 2022.

The move to shut down the site is part of the company’s cost-cutting programme announced in March 2023, aimed at saving £300 million (€350.9 million) over three years.

Shares in the company were up more than 2% by 10:00 GMT.

In February, the British consumer healthcare giant said that its first-quarter organic revenue growth would slow, citing a tepid cold and flu season and cooling China demand.

Despite price increases, Haleon’s roster of products has largely kept cheaper private-label competition at bay, although the cost-of-living squeeze and competition among painkiller brands are allowing rivals to catch up.

The company announced the appointment of Tate & Lyle executive Dawn Allen as its new chief financial officer, effective 1 November 2024.

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories